SI2477611T1 - Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo - Google Patents

Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo

Info

Publication number: SI2477611T1
Authority: SI; Slovenia
Prior art keywords: trifluormethylphenyl; cyano; hydroxy; enoic acid; improved stability
Prior art date: 2009-09-18

Application number

SI201031476A

Other languages

English (en)

Inventor

Gerrit Hauck

Original Assignee

Sanofi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-18

Filing date

2010-09-14

Publication date

2017-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2477611(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-14 Application filed by Sanofi filed Critical Sanofi

2017-07-31 Publication of SI2477611T1 publication Critical patent/SI2477611T1/sl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Otolaryngology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SI201031476A 2009-09-18 2010-09-14 Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo SI2477611T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP09290716		2009-09-18
US36338210P	2010-07-12	2010-07-12
EP10752585.9A EP2477611B1 (en)	2009-09-18	2010-09-14	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
PCT/EP2010/063439 WO2011032929A1 (en)	2009-09-18	2010-09-14	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability

Publications (1)

Publication Number	Publication Date
SI2477611T1 true SI2477611T1 (sl)	2017-07-31

Family

ID=41510564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201031476A SI2477611T1 (sl)	2009-09-18	2010-09-14	Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo

Country Status (40)

Country	Link
US (5)	US20120172427A1 (sl)
EP (1)	EP2477611B1 (sl)
JP (1)	JP2013505213A (sl)
KR (1)	KR101547880B1 (sl)
CN (4)	CN102596184B (sl)
AR (1)	AR078383A1 (sl)
AU (2)	AU2010297357B2 (sl)
BR (1)	BR112012006184B1 (sl)
CA (1)	CA2772275A1 (sl)
CL (1)	CL2015000047A1 (sl)
CO (1)	CO6511244A2 (sl)
CR (2)	CR20170078A (sl)
CY (1)	CY1119364T1 (sl)
DK (1)	DK2477611T3 (sl)
DO (1)	DOP2012000070A (sl)
ES (1)	ES2625731T3 (sl)
GT (1)	GT201200075A (sl)
HK (2)	HK1206244A1 (sl)
HN (1)	HN2012000576A (sl)
HR (1)	HRP20170904T1 (sl)
HU (1)	HUE032963T2 (sl)
IL (3)	IL218492A (sl)
JO (1)	JO3327B1 (sl)
LT (1)	LT2477611T (sl)
MA (1)	MA33585B1 (sl)
ME (1)	ME02765B (sl)
MX (1)	MX336663B (sl)
MY (1)	MY155613A (sl)
NZ (2)	NZ617025A (sl)
PE (2)	PE20152031A1 (sl)
PL (1)	PL2477611T3 (sl)
PT (1)	PT2477611T (sl)
RS (1)	RS56074B1 (sl)
RU (2)	RU2681079C2 (sl)
SI (1)	SI2477611T1 (sl)
TN (1)	TN2012000061A1 (sl)
TW (2)	TWI522130B (sl)
UA (2)	UA115979C2 (sl)
UY (1)	UY32889A (sl)
WO (1)	WO2011032929A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ617025A (en) *	2009-09-18	2014-03-28	Sanofi Sa	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
RU2493845C1 (ru) *	2012-06-07	2013-09-27	Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ"	Композиция для лечения рассеянного склероза (варианты)
KR20160079123A (ko) *	2013-11-22	2016-07-05	젠자임 코포레이션	신경변성 질병을 치료하기 위한 신규한 방법
CN103656657A (zh) *	2013-12-18	2014-03-26	北京科源创欣科技有限公司	特立氟胺药物组合物及制备方法
KR102479693B1 (ko)	2014-03-26	2022-12-22	아스텍스 테라퓨틱스 리미티드	조합물
US20160058730A1 (en) *	2014-08-29	2016-03-03	Cadila Healthcare Limited	Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) *	2014-11-18	2016-05-26	Lupin Limited	Oral pharmaceutical composition of teriflunomide
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016189406A1 (en)	2015-05-23	2016-12-01	Ftf Pharma Private Limited	Pharmaceutical composition of teriflunomide
JP6917375B2 (ja) *	2015-09-01	2021-08-11	ザ・ブロード・インスティテュート・インコーポレイテッド	血液がんの治療または予防に有用な化合物および方法
WO2017037645A1 (en) *	2015-09-02	2017-03-09	Leiutis Pharmaceuticals Pvt Ltd	Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) *	2015-09-28	2017-04-06	Natco Pharma Limited	Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) *	2016-01-20	2017-07-27	Emcure Pharmaceuticals Limited	Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar)	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
LT3999038T (lt) *	2019-07-17	2024-03-25	Cytokinetics, Inc.	Širdies sarkomerų inhibitoriaus geriamosios vaistinės formos
WO2022085015A1 (en) *	2020-10-24	2022-04-28	V-Ensure Pharma Technologies Private Limited	A solid oral composition of teriflunomide
GR1010137B (el)	2020-12-15	2021-12-07	Φαρματεν Α.Β.Ε.Ε.,	Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) *	2020-12-30	2022-07-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A film coated tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3852294A (en) *	1968-08-27	1974-12-03	Merck Patent Gmbh	Bis-quaternary pyridinium salts
US5268382A (en)	1985-09-27	1993-12-07	Hoechst Aktiengesellschaft	Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de)	1985-09-27	1987-04-02	Hoechst Ag	Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US6133301A (en)	1991-08-22	2000-10-17	Aventis Pharma Deutschland Gmbh	Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) *	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
HU222888B1 (hu)	1994-10-17	2003-12-29	Hoechst Pharmaceuticals & Chemicals K.K.	Anilid vegyületek alkalmazása I típusú allergiás betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
ES2166205T3 (es)	1997-08-08	2002-04-01	Aventis Pharma Gmbh	Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004500380A (ja)	2000-02-15	2004-01-08	テバ　ファーマシューティカル　インダストリーズ　リミティド	レフルノミドの合成方法
EP1381356B1 (en)	2001-04-05	2008-05-28	Aventis Pharmaceuticals Inc.	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) *	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en)	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
ATE495739T1 (de) *	2003-08-29	2011-02-15	Transform Pharmaceuticals Inc	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
GB2394660A (en)	2003-12-17	2004-05-05	Niche Generics Ltd	Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) *	2004-07-30	2006-02-02	The University Of Chicago	Methods and compositions for reducing toxicity associated with leflunomide treatment
KR20070065888A (ko) *	2004-10-19	2007-06-25	아벤티스 파마슈티칼스 인크.	염증성 장질환을 치료하기 위한(ｚ)-2-시아노-3-하이드록시-부트-2-엔산-(4'-트리플루오로메틸페닐)-아미드의 용도
TWI275029B (en) *	2005-11-18	2007-03-01	Hon Hai Prec Ind Co Ltd	An embedded system and method for processing data thereof
WO2007086891A1 (en)	2006-01-24	2007-08-02	Teva Pharmaceutical Industries Ltd.	Levetiracetam formulations and methods for their manufacture
DE102006017896A1 (de) *	2006-04-13	2007-10-25	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en)	2007-05-08	2009-05-06	Ulrike Wiebelitz	Therapy of benign prostatic hyperplasia (bph)
NZ617025A (en) *	2009-09-18	2014-03-28	Sanofi Sa	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2762135A1 (en) *	2013-02-04	2014-08-06	Sanofi	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

2010
- 2010-09-14 NZ NZ617025A patent/NZ617025A/en unknown
- 2010-09-14 HU HUE10752585A patent/HUE032963T2/en unknown
- 2010-09-14 WO PCT/EP2010/063439 patent/WO2011032929A1/en active Application Filing
- 2010-09-14 CN CN201080041529.8A patent/CN102596184B/zh active Active
- 2010-09-14 KR KR1020127006940A patent/KR101547880B1/ko active IP Right Grant
- 2010-09-14 US US13/395,586 patent/US20120172427A1/en not_active Abandoned
- 2010-09-14 NZ NZ598744A patent/NZ598744A/xx unknown
- 2010-09-14 CA CA2772275A patent/CA2772275A1/en not_active Abandoned
- 2010-09-14 RS RS20170589A patent/RS56074B1/sr unknown
- 2010-09-14 PT PT107525859T patent/PT2477611T/pt unknown
- 2010-09-14 BR BR112012006184-4A patent/BR112012006184B1/pt active IP Right Grant
- 2010-09-14 SI SI201031476A patent/SI2477611T1/sl unknown
- 2010-09-14 PL PL10752585T patent/PL2477611T3/pl unknown
- 2010-09-14 MX MX2012003122A patent/MX336663B/es unknown
- 2010-09-14 AU AU2010297357A patent/AU2010297357B2/en active Active
- 2010-09-14 JP JP2012529234A patent/JP2013505213A/ja not_active Abandoned
- 2010-09-14 CN CN201510052300.9A patent/CN104666238B/zh not_active Ceased
- 2010-09-14 PE PE2015002059A patent/PE20152031A1/es active IP Right Grant
- 2010-09-14 ES ES10752585.9T patent/ES2625731T3/es active Active
- 2010-09-14 UA UAA201409985A patent/UA115979C2/uk unknown
- 2010-09-14 ME MEP-2017-134A patent/ME02765B/me unknown
- 2010-09-14 CN CN201510052347.5A patent/CN104666272A/zh active Pending
- 2010-09-14 RU RU2015151938A patent/RU2681079C2/ru active
- 2010-09-14 PE PE2012000342A patent/PE20121478A1/es not_active Application Discontinuation
- 2010-09-14 UA UAA201204827A patent/UA107582C2/ru unknown
- 2010-09-14 DK DK10752585.9T patent/DK2477611T3/en active
- 2010-09-14 CR CR20170078A patent/CR20170078A/es unknown
- 2010-09-14 LT LTEP10752585.9T patent/LT2477611T/lt unknown
- 2010-09-14 CN CN201510052299.XA patent/CN104739821B/zh not_active Ceased
- 2010-09-14 RU RU2012115459/15A patent/RU2012115459A/ru unknown
- 2010-09-14 MY MYPI2012000646A patent/MY155613A/en unknown
- 2010-09-14 EP EP10752585.9A patent/EP2477611B1/en not_active Revoked
- 2010-09-16 UY UY0001032889A patent/UY32889A/es not_active Application Discontinuation
- 2010-09-16 AR ARP100103381A patent/AR078383A1/es not_active Application Discontinuation
- 2010-09-16 JO JOP/2010/0317A patent/JO3327B1/ar active
- 2010-09-16 TW TW103142089A patent/TWI522130B/zh active
- 2010-09-16 TW TW99131364A patent/TWI468190B/zh active
2012
- 2012-02-10 TN TNP2012000061A patent/TN2012000061A1/en unknown
- 2012-03-05 IL IL218492A patent/IL218492A/en active IP Right Grant
- 2012-03-12 CR CR20120116A patent/CR20120116A/es unknown
- 2012-03-13 MA MA34687A patent/MA33585B1/fr unknown
- 2012-03-15 CO CO12045392A patent/CO6511244A2/es active IP Right Grant
- 2012-03-16 GT GT201200075A patent/GT201200075A/es unknown
- 2012-03-16 US US13/422,494 patent/US8802735B2/en active Active
- 2012-03-16 HN HN2012000576A patent/HN2012000576A/es unknown
- 2012-03-16 DO DO2012000070A patent/DOP2012000070A/es unknown
2013
- 2013-11-18 AU AU2013257516A patent/AU2013257516B2/en active Active
2014
- 2014-04-30 US US14/265,433 patent/US20140235888A1/en not_active Abandoned
2015
- 2015-01-08 CL CL2015000047A patent/CL2015000047A1/es unknown
- 2015-07-16 HK HK15106785.9A patent/HK1206244A1/xx unknown
- 2015-07-16 HK HK15106786.8A patent/HK1206245A1/xx unknown
2016
- 2016-03-28 IL IL244809A patent/IL244809B/en active IP Right Grant
- 2016-10-11 US US15/290,677 patent/US20170247319A1/en not_active Abandoned
2017
- 2017-06-13 HR HRP20170904TT patent/HRP20170904T1/hr unknown
- 2017-07-04 CY CY20171100710T patent/CY1119364T1/el unknown
2018
- 2018-08-20 US US15/999,565 patent/US20190241505A1/en not_active Abandoned
2019
- 2019-02-19 IL IL26491219A patent/IL264912B/en active IP Right Grant

Also Published As

Publication number	Publication date
WO2011032929A1 (en)	2011-03-24
TW201117838A (en)	2011-06-01
EP2477611A1 (en)	2012-07-25
CN104666238A (zh)	2015-06-03
US20190241505A1 (en)	2019-08-08
AU2010297357B2 (en)	2013-11-07
NZ617025A (en)	2014-03-28
BR112012006184B1 (pt)	2022-10-18
CN104739821B (zh)	2018-04-06
HK1206245A1 (en)	2016-01-08
US8802735B2 (en)	2014-08-12
UY32889A (es)	2011-04-29
JP2013505213A (ja)	2013-02-14
IL218492A0 (en)	2012-04-30
IL264912B (en)	2019-11-28
MY155613A (en)	2015-11-13
IL244809A0 (en)	2016-04-21
MA33585B1 (fr)	2012-09-01
TWI522130B (zh)	2016-02-21
HUE032963T2 (en)	2017-11-28
CN102596184B (zh)	2015-03-11
RU2681079C2 (ru)	2019-03-04
UA115979C2 (uk)	2018-01-25
CR20170078A (es)	2017-05-22
MX2012003122A (es)	2012-04-10
TN2012000061A1 (en)	2013-09-19
CN104666272A (zh)	2015-06-03
IL218492A (en)	2016-04-21
AR078383A1 (es)	2011-11-02
HN2012000576A (es)	2015-01-26
BR112012006184A2 (pt)	2016-05-31
US20170247319A1 (en)	2017-08-31
PE20152031A1 (es)	2016-01-14
AU2010297357A1 (en)	2012-04-05
CN102596184A (zh)	2012-07-18
GT201200075A (es)	2014-05-14
EP2477611B1 (en)	2017-04-05
UA107582C2 (uk)	2015-01-26
KR101547880B1 (ko)	2015-08-27
NZ598744A (en)	2013-11-29
RU2012115459A (ru)	2013-10-27
MX336663B (es)	2016-01-27
TW201517935A (zh)	2015-05-16
US20120172427A1 (en)	2012-07-05
TWI468190B (zh)	2015-01-11
CN104739821A (zh)	2015-07-01
RS56074B1 (sr)	2017-10-31
US20120208880A1 (en)	2012-08-16
RU2015151938A3 (sl)	2019-01-15
CY1119364T1 (el)	2018-02-14
CL2015000047A1 (es)	2015-06-12
PL2477611T3 (pl)	2017-09-29
JO3327B1 (ar)	2019-03-13
LT2477611T (lt)	2017-06-26
CA2772275A1 (en)	2011-03-24
KR20120089461A (ko)	2012-08-10
RU2015151938A (ru)	2019-01-15
ME02765B (me)	2018-01-20
AU2013257516B2 (en)	2015-09-17
CO6511244A2 (es)	2012-08-31
HK1206244A1 (en)	2016-01-08
HRP20170904T1 (hr)	2017-09-08
PE20121478A1 (es)	2012-11-12
IL244809B (en)	2019-03-31
PT2477611T (pt)	2017-06-05
US20140235888A1 (en)	2014-08-21
DOP2012000070A (es)	2012-05-31
DK2477611T3 (en)	2017-07-10
CN104666238B (zh)	2018-04-06
CR20120116A (es)	2012-06-15
ES2625731T3 (es)	2017-07-20

Publication	Publication Date	Title
IL264912B (en)	2019-11-28	Tablet formulations of -(z)2-cyano-3-hydroxy-but-2 enoic acid - ('4 trifluoromethylphenyl) - amide with improved stability
AU2013257516A1 (en)	2013-12-05	(Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
GB0720716D0 (en)	2007-12-05	Novel formulation
GB0810615D0 (en)	2008-07-16	Novel pharmaceutical
GB0806978D0 (en)	2008-05-21	Novel formulations
EP2448934A4 (en)	2012-12-05	DERIVATIVES OF 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN
HK1156844A1 (en)	2012-06-22	Pharmaceutical composition 271 271
ZA201007197B (en)	2011-06-29	Raloxifene pharmaceutical formulations
PL2379057T3 (pl)	2013-12-31	Preparaty fenylefryny o poprawionej stabilności
GB0810617D0 (en)	2008-07-16	Novel pharmaceutical
PT2568970T (pt)	2019-02-11	Formulações farmacêuticas estáveis contendo um anti-histamínico
EP2513131A4 (en)	2013-10-16	NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES
HK1182939A1 (en)	2013-12-13	Stable pharmaceutical composition
GB0804485D0 (en)	2008-04-16	Novel pharmaceutical compositions
GB0805807D0 (en)	2008-04-30	Novel pharmaceutical compositions
GB0813121D0 (en)	2008-08-27	Novel formulations
SI2271321T1 (sl)	2012-10-30	Farmacevtski sestavek 271
IL200640A0 (en)	2010-05-17	Caloguide"
GB0701367D0 (en)	2007-03-07	Novel pharmaceutical compositions
GB0713794D0 (en)	2007-08-22	Novel pharmaceutical compositions
GB0704749D0 (en)	2007-04-18	Novel pharmaceutical compositions
GB0701368D0 (en)	2007-03-07	Novel pharmaceutical compositions
GB0701364D0 (en)	2007-03-07	Novel pharmaceutical compositions
GB0720719D0 (en)	2007-12-05	Novel formulation
GB0810217D0 (en)	2008-07-09	Pharmaceutical formulations